1. Home
  2. HYFT vs LUNG Comparison

HYFT vs LUNG Comparison

Compare HYFT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HYFT

MindWalk Holdings Corp.

HOLD

Current Price

$1.34

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.28

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYFT
LUNG
Founded
1983
1995
Country
United States
United States
Employees
102
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.9M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HYFT
LUNG
Price
$1.34
$1.28
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$5.00
$5.38
AVG Volume (30 Days)
161.4K
496.8K
Earning Date
03-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
$29.18
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.99
$1.13
52 Week High
$3.00
$3.88

Technical Indicators

Market Signals
Indicator
HYFT
LUNG
Relative Strength Index (RSI) 57.22 44.67
Support Level $1.02 $1.27
Resistance Level $1.48 $1.45
Average True Range (ATR) 0.09 0.09
MACD 0.01 0.00
Stochastic Oscillator 65.15 35.19

Price Performance

Historical Comparison
HYFT
LUNG

About HYFT MindWalk Holdings Corp.

MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: